Prevention and treatment of FGFR inhibitor-associated toxicities.
Cholangiocarcinoma
FGFR
Hyperphosphatemia
Personalized medicine
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
21
04
2020
revised:
30
07
2020
accepted:
17
08
2020
pubmed:
23
9
2020
medline:
31
10
2020
entrez:
22
9
2020
Statut:
ppublish
Résumé
Fibroblast growth factor receptor (FGFR) inhibitors have shown promising results in terms of objective response rates in phase I/II trials in various malignancies that harbor FGFR genetic aberrations. The class of medications brings in the concept of 'personalized' treatment by targeting susceptible FGFR genetic alterations in some rare but dismal cancers such as cholangiocarcinoma. Despite the fact that FGFR inhibitors are well-tolerated, these drugs are associated with toxicities that are distinct from that of other small-molecule tyrosine kinase inhibitors. These toxicities can result in dose reductions, interruptions, and even drug discontinuation as reported in the clinical trials. The prevention and effective management of the FGFR inhibitor-associated toxicities will allow patients to stay on these medications without the therapy interruptions. The current work is focused on summarizing the available literature on unique FGFR inhibitor-associated toxicities with a special emphasis in managing the unique adverse events.
Identifiants
pubmed: 32961472
pii: S1040-8428(20)30227-4
doi: 10.1016/j.critrevonc.2020.103091
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Receptors, Fibroblast Growth Factor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103091Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.